phenylcarbamates

Summary

Summary: Phenyl esters of carbamic acid or of N-substituted carbamic acids. Structures are similar to PHENYLUREA COMPOUNDS with a carbamate in place of the urea.

Top Publications

  1. pmc Impact of three years of large scale Indoor Residual Spraying (IRS) and Insecticide Treated Nets (ITNs) interventions on insecticide resistance in Anopheles gambiae s.l. in Benin
    Gil Germain Padonou
    Faculté des Sciences et Techniques de l Université d Abomey Calavi, Calavi, Benin
    Parasit Vectors 5:72. 2012
  2. ncbi Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies
    Shrinidh A Joshi
    TIFAC Centre of Relevance and Excellence, Centre of PG studies and Research, Pharmacy Department, The Maharaja Sayajirao University of Baroda, Donors Plaza, Fatehgunj, Vadodara 390002, Gujarat, India
    Eur J Pharm Biopharm 76:189-99. 2010
  3. ncbi Protective effect of rivastigmine against 3-nitropropionic acid-induced Huntington's disease like symptoms: possible behavioural, biochemical and cellular alterations
    Puneet Kumar
    Pharmacology Division, University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh 160014, India
    Eur J Pharmacol 615:91-101. 2009
  4. ncbi Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease
    Rafael Blesa
    Hospital de la Sta Creu i Sant Pau, Barcelona, Spain
    Neurology 69:S23-8. 2007
  5. ncbi Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study
    Aurelia Santoro
    Department of Experimental Pathology, University of Bologna, Via S Giacomo 12, Bologna, Italy
    CNS Drugs 24:163-76. 2010
  6. ncbi The residual life of bendiocarb: a field-based evaluation from Mozambique
    Rajendra Maharaj
    Malaria Research Programme, Medical Research Council, Durban, 4067, South Africa
    J Med Entomol 41:130-2. 2004
  7. ncbi A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule
    Bengt Winblad
    Karolinska Institutet Alzheimer Research Center, Stockholm, Sweden
    Int J Geriatr Psychiatry 22:456-67. 2007
  8. ncbi The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer's disease
    Martin R Farlow
    Department of Neurology, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Curr Med Res Opin 26:2441-7. 2010
  9. ncbi Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease
    G T Grossberg
    Department of Neurology and Psychiatry, St Louis University School of Medicine, St Louis, MO 63104, USA
    Int J Clin Pract 65:465-71. 2011
  10. ncbi A large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD: the EXTEND Study
    Serge Gauthier
    McGill Centre for Studies in Aging, Douglas Hospital, Montreal, Quebec, Canada
    Curr Med Res Opin 22:2251-65. 2006

Research Grants

  1. Rivastigmine as a Treatment for Methamphetamine Dependence
    Richard De La Garza; Fiscal Year: 2010
  2. Transdisciplinary Imaging Genetics Center (1 of 2)(RMI)
    Steven Potkin; Fiscal Year: 2006
  3. Development of Inventory of Depressive Symptomatology
    PUDUGRAMAM DORAISWAMY; Fiscal Year: 2005
  4. Treatment Outcomes of Vascular Depression
    PUDUGRAMAM DORAISWAMY; Fiscal Year: 2005
  5. Pilot Study of Huperzine A in Alzheimer's Disease
    Paul Aisen; Fiscal Year: 2003
  6. BRAIN GALANIN RECEPTORS AND EPILEPSY
    Andrey Mazarati; Fiscal Year: 2006
  7. Guanfacine Treatment for Prefrontal Cognitive Dysfunction in Elderly Subjects
    Christopher H van Dyck; Fiscal Year: 2010
  8. GI PEPTIDE SIGNALING THROUGH TYROSINE PHOSPHORYLATION
    JUAN ENRIQUE ROZENGURT; Fiscal Year: 2010
  9. The 5-HT7 receptor in models of psychiatric disorders
    PETER HEDLUND; Fiscal Year: 2009
  10. MENTAL DISORDERS OF AGING--ANTIINFLAMMATION IN AD
    Gary Small; Fiscal Year: 2003

Detail Information

Publications224 found, 100 shown here

  1. pmc Impact of three years of large scale Indoor Residual Spraying (IRS) and Insecticide Treated Nets (ITNs) interventions on insecticide resistance in Anopheles gambiae s.l. in Benin
    Gil Germain Padonou
    Faculté des Sciences et Techniques de l Université d Abomey Calavi, Calavi, Benin
    Parasit Vectors 5:72. 2012
    ..We assessed the impact of this campaign on phenotypic resistance, kdr (knock-down resistance) and ace-1(R) (insensitive acetylcholinesterase) mutations...
  2. ncbi Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies
    Shrinidh A Joshi
    TIFAC Centre of Relevance and Excellence, Centre of PG studies and Research, Pharmacy Department, The Maharaja Sayajirao University of Baroda, Donors Plaza, Fatehgunj, Vadodara 390002, Gujarat, India
    Eur J Pharm Biopharm 76:189-99. 2010
    ..This indicates rapid and higher extent of transport of RT into the mice brain and thus shows the suitability of both NPs as potential carriers for providing sustained brain delivery of RT...
  3. ncbi Protective effect of rivastigmine against 3-nitropropionic acid-induced Huntington's disease like symptoms: possible behavioural, biochemical and cellular alterations
    Puneet Kumar
    Pharmacology Division, University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh 160014, India
    Eur J Pharmacol 615:91-101. 2009
    ..The results show that rivastigmine could be used as an effective therapeutic agent in the management of Huntington's disease and related conditions...
  4. ncbi Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease
    Rafael Blesa
    Hospital de la Sta Creu i Sant Pau, Barcelona, Spain
    Neurology 69:S23-8. 2007
    ..Preference for the patch may indicate reduced caregiver stress, substantiated by greater satisfaction and less interference with daily life. These benefits may lead to improved compliance...
  5. ncbi Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study
    Aurelia Santoro
    Department of Experimental Pathology, University of Bologna, Via S Giacomo 12, Bologna, Italy
    CNS Drugs 24:163-76. 2010
    ..g. health status and co-morbidities) associated with a complex disease such as AD in elderly people...
  6. ncbi The residual life of bendiocarb: a field-based evaluation from Mozambique
    Rajendra Maharaj
    Malaria Research Programme, Medical Research Council, Durban, 4067, South Africa
    J Med Entomol 41:130-2. 2004
    ..The different types of surfaces sprayed did not affect the residual life of bendiocarb. Therefore, to achieve effective control in a malaria-endemic area such as southern Mozambique, two spray rounds per annum are necessary...
  7. ncbi A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule
    Bengt Winblad
    Karolinska Institutet Alzheimer Research Center, Stockholm, Sweden
    Int J Geriatr Psychiatry 22:456-67. 2007
    ..To compare the efficacy, safety and tolerability of a novel rivastigmine transdermal patch with conventional rivastigmine capsules and placebo in patients with Alzheimer's disease (AD)...
  8. ncbi The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer's disease
    Martin R Farlow
    Department of Neurology, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Curr Med Res Opin 26:2441-7. 2010
    ..Earlier studies have demonstrated the efficacy of rivastigmine in severe Alzheimer's disease (AD), and supported the use of a higher dose patch in AD...
  9. ncbi Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease
    G T Grossberg
    Department of Neurology and Psychiatry, St Louis University School of Medicine, St Louis, MO 63104, USA
    Int J Clin Pract 65:465-71. 2011
    ..The efficacy of oral rivastigmine appears to be dose-dependent. The current analysis investigates the effect of dose on the efficacy of the rivastigmine transdermal patch...
  10. ncbi A large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD: the EXTEND Study
    Serge Gauthier
    McGill Centre for Studies in Aging, Douglas Hospital, Montreal, Quebec, Canada
    Curr Med Res Opin 22:2251-65. 2006
    ....
  11. ncbi Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study
    Howard H Feldman
    Division of Neurology, University of British Columbia Hospital, Vancouver, Canada
    Lancet Neurol 6:501-12. 2007
    ..To assess the effect of rivastigmine in patients with mild cognitive impairment (MCI) on the time to clinical diagnosis of Alzheimer's disease (AD) and the rate of cognitive decline...
  12. ncbi Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy
    Martin R Farlow
    Department of Neurology, Indiana University School of Medicine, Indianapolis, IN, USA
    Int J Geriatr Psychiatry 26:1236-43. 2011
    ..This exploratory, hypothesis-forming analysis assessed response to rivastigmine according to severity of dementia at baseline...
  13. ncbi The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease
    Sarah Thompson
    Sunnybrook and Women s College Health Sciences Centre, Department of Psychiatry, Rm FG 05, 2075 Bayview Avenue, Toronto, ON, M4N 3M5, Canada
    Expert Opin Drug Saf 3:425-40. 2004
    ..Further study is needed to examine other indications for ChEIs, as well as their combination with newer treatments, such as memantine...
  14. ncbi Predicting time to nursing home placement based on activities of daily living scores--a modelling analysis using data on Alzheimer's disease patients receiving rivastigmine or donepezil
    Hind T Hatoum
    Center for Pharmacoeconomic Research, the University of Illinois at Chicago UIC, Chicago, IL, USA
    J Med Econ 12:98-103. 2009
    ..To quantify the impact of activities of daily living (ADL) scores on the risk of nursing home placement (NHP) in Alzheimer's disease (AD) patients...
  15. ncbi Risk factors for nursing home placement in Alzheimer's disease: a longitudinal study of cognition, ADL, service utilization, and cholinesterase inhibitor treatment
    Carina Wattmo
    Department of Neuropsychiatry, Skane University Hospital, SE 205 02 Malmo, Sweden
    Gerontologist 51:17-27. 2011
    ....
  16. ncbi Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression
    M R Farlow
    Department of Neurology, Indiana University School of Medicine, CL583, 541 Clinical Dr, Indianapolis, IN 46202 5111, USA
    Arch Neurol 58:417-22. 2001
    ..Evidence suggests that disease severity predicts the response of patients with Alzheimer disease (AD) to cholinesterase inhibitor treatment, raising the question of whether disease progression also predicts response to this treatment...
  17. ncbi Guidelines for managing Alzheimer's disease: Part II. Treatment
    Jeffrey L Cummings
    University of California, Los Angeles, School of Medicine, USA
    Am Fam Physician 65:2525-34. 2002
    ..Throughout the course of the disease, routine use of community resources allows care to be provided by a network of professionals, many of whom will be specialists in Alzheimer's disease...
  18. ncbi Long-term effects of rivastigmine in moderately severe Alzheimer's disease: does early initiation of therapy offer sustained benefits?
    P Murali Doraiswamy
    Department of Psychiatry, Duke University Medical Center, Durham, NC 27710, USA
    Prog Neuropsychopharmacol Biol Psychiatry 26:705-12. 2002
    ..The results support the value of early treatment of AD patients, particularly those with moderately severe AD...
  19. ncbi Acetylcholinesterase inhibitors reduce brain and blood interleukin-1beta production
    Yehuda Pollak
    Department of Psychology, The Hebrew University of Jerusalem, Jerusalem, Israel
    Ann Neurol 57:741-5. 2005
    ..These findings demonstrate that cholinergic enhancement produces central and peripheral antiinflammatory effects and suggest a novel therapeutic mechanism for acetylcholinesterase inhibitors...
  20. ncbi Effects of huperzine A on acetylcholinesterase isoforms in vitro: comparison with tacrine, donepezil, rivastigmine and physostigmine
    Qin Zhao
    State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, People s Republic of China
    Eur J Pharmacol 455:101-7. 2002
    ..These results suggest that the use of acetylcholinesterase inhibitors in treatment of Alzheimer's disease must consider both form-specific and region-specific characteristics of acetylcholinesterase inhibition...
  21. ncbi Effects of oral rivastigmine on cognitive domains in mild-to-moderate Alzheimer's disease
    Martin R Farlow
    Indiana University School of Medicine, Indianapolis, USA
    Am J Alzheimers Dis Other Demen 25:347-52. 2010
    ..Evaluation of ADAS-cog domain scores provides insight into test items most likely to respond to treatment...
  22. ncbi A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease
    Yahya Karaman
    Erciyes University, Medical Faculty, Department of Neurology, TR 38039 Kayseri, Turkey
    Dement Geriatr Cogn Disord 19:51-6. 2005
    ..Long-term rivastigmine treatment appeared to be well tolerated in patients with advanced moderate AD and significantly benefits the cognitive and functional symptoms of AD...
  23. ncbi Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses
    Gustavo Alva
    ATP Clinical Research, Costa Mesa, CA, USA
    Int J Geriatr Psychiatry 26:356-63. 2011
    ..The aim of this retrospective analysis was to further evaluate the treatment effects of rivastigmine on individual ADL items...
  24. ncbi Reviews: Effects of transdermal rivastigmine on ADAS-cog items in mild-to-moderate Alzheimer's disease
    George T Grossberg
    St Louis University School of Medicine, MO 63104, USA
    Am J Alzheimers Dis Other Demen 25:627-33. 2010
    ..Rivastigmine patch was associated with improvements on the memory, praxis, and language domains of cognition in patients with mild-to-moderate AD...
  25. pmc Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine
    Qian sheng Yu
    Drug Design and Development Section, Laboratory of Neurosciences, Biomedical Research Center, National Institute on Aging, National Institutes of Health, 251 Bayview Blvd, Baltimore, MD 21224, USA
    Bioorg Med Chem 18:4687-93. 2010
    ..An extended duration of cholinesterase inhibition was determined in rodent, making them of potential interest as long-acting agents for myasthenia gravis...
  26. ncbi Spectrophotometric and spectrodensitometric methods for the determination of rivastigmine hydrogen tartrate in presence of its degradation product
    Maissa Y Salem
    Analytical Chemistry Department, Faculty of Pharmacy, Cairo University, Kasr El Aini Street, Cairo, Egypt
    Drug Test Anal 2:225-33. 2010
    ..The proposed methods have been successfully applied to the analysis of RIV in pharmaceutical dosage forms without interference from other dosage form additives and the results were statistically compared with reference method...
  27. ncbi Investigation of liposome formulation effects on rivastigmine transport through human colonic adenocarcinoma cell line (CACO-2)
    Z Degim
    Department of Pharmaceutical Technology, Gazi University Faculty of Pharmacy, Ankara, Turkey
    Pharmazie 65:32-40. 2010
    ..The highest value of AChE inhibition was observed for rivastigmine and sodium taurocholate liposomes. The histological investigations and observations also supported these results...
  28. ncbi O-glycosylation of FoxO1 increases its transcriptional activity towards the glucose 6-phosphatase gene
    Meishiue Kuo
    Institut Cochin, Universite Paris Descartes, 22 rue Mechain, CNRS UMR 8104, Paris, France
    FEBS Lett 582:829-34. 2008
    ..Since glucose-6-phosphatase plays a key role in hepatic glucose production, our observation may be of importance with regard to glucotoxicity associated with chronic hyperglycaemia in diabetes...
  29. ncbi Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period
    Roger Bullock
    Kingshill Research Centre, Victoria Hospital, Swindon, UK
    Curr Med Res Opin 21:1317-27. 2005
    ....
  30. ncbi Effect of anti-dementia drugs on LPS induced neuroinflammation in mice
    Ethika Tyagi
    Division of Pharmacology, Central Drug Research Institute, Lucknow 226001, India
    Life Sci 80:1977-83. 2007
    ..The present study indicate that cholinesterase inhibitor anti-dementia drugs are effective against LPS induced neuroinflammation that may be linked to enhanced cholinergic activity...
  31. ncbi Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials
    Harish Kavirajan
    Department of General Internal Medicine, Division of Health Services Research, Veterans Affairs Greater Los Angeles Health Care System, CA, USA
    Lancet Neurol 6:782-92. 2007
    ..A systematic review and meta-analysis was undertaken to assess the evidence for efficacy and safety of cholinesterase inhibitors and memantine in vascular dementia...
  32. ncbi Use of antidementia agents in vascular dementia: beyond Alzheimer disease
    Martin R Farlow
    Department of Neurology, Indiana University School of Medicine, CL 299, 541 Clinical Dr, Indianapolis, IN 46202, USA
    Mayo Clin Proc 81:1350-8. 2006
    ..These data suggest that antidementia drugs currently used for treatment of AD should be considered for treatment of VaD as well...
  33. ncbi The effect of cholinesterase inhibitors on the regional blood flow in patients with Alzheimer's disease and vascular dementia
    Wanda Lojkowska
    Institute of Psychiatry and Neurology, Sobieskiego 9, 02 957, Warsaw, Poland
    J Neurol Sci 216:119-26. 2003
    ..Increased levels of acetylcholine in the brain after ChE-I treatment may support the cholinergic regulation of rCBF, and in result increase it. Such effects seem to be more pronounced in the more affected brain regions...
  34. ncbi Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease
    A Burns
    University of Manchester, Wythenshawe Hospital, Manchester, UK
    Int J Geriatr Psychiatry 19:243-9. 2004
    ..Cholinesterase (ChE) inhibitors are primarily used in the treatment of mild to moderate Alzheimer's disease (AD), but may also be effective in more severe disease...
  35. ncbi Suppression of neuroinflammation and immunomodulation by the acetylcholinesterase inhibitor rivastigmine
    Eran Nizri
    Laboratory of Neuroimmunology, Department of Neurology, Agnes Ginges Center for Human Neurogenetics, Jerusalem, Israel
    J Neuroimmunol 203:12-22. 2008
    ..These effects were abolished by alpha7 nicotinic acetylcholine receptor antagonists. Antigen presentation was also affected by this treatment. Thus, rivastigmine treatment had immunomodulatory activity in EAE...
  36. ncbi Different responses to rivastigmine in subcortical vascular dementia and multi-infarct dementia
    Rita Moretti
    Department of Medicine and Neurology, University of Trieste, Trieste, Italy
    Am J Alzheimers Dis Other Demen 23:167-76. 2008
    ..It also suggests that rivastigmine may enable a reduction in concomitant neuroleptics and benzodiazepines in VaD, especially in MID. The results are discussed with an overview of the literature...
  37. ncbi Long-term outcome and prediction models of activities of daily living in Alzheimer disease with cholinesterase inhibitor treatment
    Carina Wattmo
    Department of Clinical Sciences, Clinical Memory Research Unit, Malmo, Lund University, Sweden
    Alzheimer Dis Assoc Disord 25:63-72. 2011
    ..AD severity at baseline is a key factor in obtaining reliable clinical prognoses of the long-term ADL ability. The dosage of ChEI treatment could possibly lead to a different functional outcome...
  38. ncbi Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years
    G W Small
    UCLA Neuropsychiatric Institute, Los Angeles, CA 90024 1759, USA
    Int J Clin Pract 59:473-7. 2005
    ..3 (+/-4.9). Projected mean scores in model-based untreated patients declined below 10 points on the MMSE at about 3 years, while the mean MMSE score of patients who remained on rivastigmine stayed above 10 points for 5 years...
  39. ncbi Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients
    G Lefevre
    Novartis Pharma AG, Basel, Switzerland
    Clin Pharmacol Ther 83:106-14. 2008
    ..Average exposure with the 10 cm2 patch was comparable to the highest capsule dose (6 mg Q12H, i.e., 12 mg/day)...
  40. ncbi Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain
    Z Rakonczay
    Alzheimer s Disease Research Center, Department of Psychiatry, University of Szeged, Szeged, Hungary
    Acta Biol Hung 54:183-9. 2003
    ..We conclude that a molecular form-specific inhibitor may have therapeutic applications in inhibiting the G1 form, which is relatively unchanged in Alzheimer's brain...
  41. ncbi Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease
    Roger Bullock
    Kingshill Research Centre, Swindon, UK
    Curr Med Res Opin 22:483-94. 2006
    ..This retrospective analysis investigated whether younger and older patients showed differential tolerability and efficacy responses to cholinesterase inhibitor treatment...
  42. ncbi Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site application
    Gilbert Lefèvre
    Novartis Pharma AG, Exploratory Development, WSJ 210 4 25, CH 4002 Basel, Switzerland
    J Clin Pharmacol 47:471-8. 2007
    ..02). Pharmacokinetic profiles and adhesiveness of the upper back, chest, and upper arm, coupled with low rates of erythema at these sites, suggest their suitability for clinical use...
  43. ncbi Potential long-term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains
    T Erkinjuntti
    Department of Neurology, Helsinki University Central Hospital, HYKS, Finland
    Int J Clin Pract 57:756-60. 2003
    ..These findings may have an important influence on the way cholinesterase inhibitors are prescribed...
  44. pmc Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease
    Howard H Feldman
    Division of Neurology, University of British Columbia, Clinic for Alzheimer s Disease and Related Disorders, Vancouver, British Columbia, Canada
    J Neurol Neurosurg Psychiatry 78:1056-63. 2007
    ..To evaluate the efficacy and safety of rapidly titrated rivastigmine administered twice (BID) or three times (TID) daily in patients with mild to moderate Alzheimer's disease (AD)...
  45. ncbi Protein O-GlcNAc modulates motility-associated signaling intermediates in neutrophils
    Zachary T Kneass
    Department of Cell Biology, MCLM 690, University of Alabama, Birmingham, Alabama 35294, USA
    J Biol Chem 280:14579-85. 2005
    ..These data indicate that O-GlcNAcylation is an important signaling element in neutrophils that modulates the activities of several critical signaling intermediates involved in the regulation of cellular movement...
  46. pmc A novel effect of rivastigmine on pre-synaptic proteins and neuronal viability in a neurodegeneration model of fetal rat primary cortical cultures and its implication in Alzheimer's disease
    Jason A Bailey
    Laboratory of Molecular Neurogenetics, Department of Psychiatry, Institute of Psychiatric Research, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    J Neurochem 112:843-53. 2010
    ....
  47. ncbi The protective effects of PUGNAc on cardiac function after trauma-hemorrhage are mediated via increased protein O-GlcNAc levels
    LuYun Zou
    Department of Cell Biology, University of Alabama at Birmingham, Birmingham, Alabama 35294 0005, USA
    Shock 27:402-8. 2007
    ..The similar effects of glucosamine and PUGNAc support the notion that the protection associated with both interventions is mediated via increased protein O-GlcNAc levels...
  48. ncbi Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period
    S Lopez-Pousa
    Unitat de Valoració de la Memòria i les demències UVaMiD, Hospital Santa Caterina, Plaça Hospital, 5, ES 17002 Girona, Espanya
    Dement Geriatr Cogn Disord 19:189-95. 2005
    ..Further studies in the context of daily clinical practice will determine the clinical significance of the changes observed. An important variability of the response to the treatment was observed in treated patients...
  49. ncbi Selective decrease of membrane-associated PKC-alpha and PKC-epsilon in response to elevated intracellular O-GlcNAc levels in transformed human glial cells
    Jason A Matthews
    Department of Chemistry, University of South Florida, 4202 East Fowler Ave, SCA 400, Tampa, FL, 33620, USA
    Biochim Biophys Acta 1743:305-15. 2005
    ..In addition, none of the three compounds affected membrane levels of PKC-iota. Altogether, these results demonstrate a novel link between increased levels of the O-GlcNAc modification and the regulation of specific PKC isoforms...
  50. ncbi New perspective for the treatment of Alzheimer diseases: liposomal rivastigmine formulations
    N Başaran Mutlu
    Department of Pharmaceutical Technology, Gazi University Faculty of Pharmacy, Ankara
    Drug Dev Ind Pharm 37:775-89. 2011
    ..Histological observations of the mice' brains were performed under transmission electron microscope (TEM). The histological results were also indicated and supported all these findings...
  51. ncbi A study of rivastigmine liposomes for delivery into the brain through intranasal route
    Karthik Arumugam
    Department of Pharmaceutical Quality Assurance, Manipal College of Pharmaceutical Sciences, Manipal, Karnataka 576104 India
    Acta Pharm 58:287-97. 2008
    ..Delivering rivastigmine liposomes through the intranasal route for the treatment of Alzheimer's disease might be a new approach to the management of this condition...
  52. ncbi Review of rivastigmine and its clinical applications in Alzheimer's disease and related disorders
    A Desai
    Department of Geriatric Psychiatry, Saint Louis University Health Sciences Center and School of Medicine, Saint Louis, MO 63104, USA
    Expert Opin Pharmacother 2:653-66. 2001
    ..Therapeutic dose range is 6 - 12 mg/day. Rivastigmine should be started at 1.5 mg b.i.d. with meals and increased at 2 - 4 week intervals to achieve the highest tolerated dose...
  53. ncbi Peripheral cholinoceptor antagonist anisodamine counteracts cholinergic adverse effects and facilitates cognitive amelioration of rivastigmine
    Wei Wei Zhang
    Department of Pharmacology, Institute of Medical Sciences, Shanghai Jiao Tong University School of Medicine, 280 South Chongqing Road, 200025 Shanghai, China
    J Neural Transm 116:1643-9. 2009
    ..25 mg/kg). These findings provide an insight into the feasibility of combined therapy with cholinesterase inhibitors and peripheral cholinoceptor antagonists for the treatment of AD...
  54. pmc Bendiocarb, a potential alternative against pyrethroid resistant Anopheles gambiae in Benin, West Africa
    Martin C Akogbeto
    Centre de Recherche Entomologique de Cotonou CREC, Cotonou, Bénin 06 BP 2604
    Malar J 9:204. 2010
    ..The goal of this study was to evaluate under field conditions the efficacy of a carbamate (bendiocarb) and an organophosphate (fenitrothion) against pyrethroid-resistant An. gambiae s.s...
  55. ncbi Rivastigmine exposure provided by a transdermal patch versus capsules
    Francois Mercier
    Novartis Pharma AG, Basel, Switzerland
    Curr Med Res Opin 23:3199-204. 2007
    ..The objective of this study was to evaluate the pharmacokinetics of rivastigmine following transdermal delivery by a patch versus oral delivery with conventional capsules in a population of AD patients...
  56. pmc Increased O-GlcNAc levels during reperfusion lead to improved functional recovery and reduced calpain proteolysis
    Jia Liu
    Department of Cell Biology, University of Alabama at Birmingham, AL 35294 0005, USA
    Am J Physiol Heart Circ Physiol 293:H1391-9. 2007
    ....
  57. ncbi Cholinesterase inhibitor treatment and urinary incontinence in Alzheimer's disease
    John M Starr
    J Am Geriatr Soc 55:800-1. 2007
  58. pmc O-linked beta-N-acetylglucosaminylation in mouse embryonic neural precursor cells
    Makoto Yanagisawa
    Institute of Molecular Medicine and Genetics and Institute of Neuroscience, Medical College of Georgia, Augusta, Georgia 30912, USA
    J Neurosci Res 87:3535-45. 2009
    ..Furthermore, in NECs, we identified an O-GlcNAc-modified protein, Sp1 transcription factor. Our study is the first to evaluate expression and functions of O-GlcNAc in NECs...
  59. ncbi Excessive O-GlcNAcylation of proteins suppresses spontaneous cardiogenesis in ES cells
    Hoe Suk Kim
    Medical Research Center, Seoul National University, Seoul, Republic of Korea
    FEBS Lett 583:2474-8. 2009
    ..These results suggest that excessive O-GlcNAcylation impairs cardiac cell differentiation in ES cells...
  60. ncbi O-GlcNAc modification of proteins affects volume regulation in Jurkat cells
    Tamas Nagy
    Department of Laboratory Medicine, Faculty of Medicine, University of Pecs, Ifjusag str 13, 7624, Pecs, Hungary
    Eur Biophys J 39:1207-17. 2010
    ..In conclusion, we demonstrate for the first time that protein O-GlcNAc could modulate cell volume regulation...
  61. ncbi Development of GlcNAc-inspired iminocyclitiols as potent and selective N-acetyl-beta-hexosaminidase inhibitors
    Ching Wen Ho
    Institute of Biological Chemistry, Academia Sinica, Taipei, Taiwan
    ACS Chem Biol 5:489-97. 2010
    ..5 x 10(5) times more selective for Hex B than for a similar human enzyme O-GlcNAcase. These glycosidase inhibitors were shown to modulate intracellular levels of glycolipids, including ganglioside-GM2 and asialoganglioside-GM2...
  62. ncbi Rivastigmine for dementia associated with Parkinson's disease
    Murat Emre
    Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
    N Engl J Med 351:2509-18. 2004
    ..Cholinergic deficits are prominent in patients who have dementia associated with Parkinson's disease. We investigated the effects of the dual cholinesterase inhibitor rivastigmine in such patients...
  63. ncbi An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting
    E Aguglia
    Department of Clinical, Morphological and Technological Science, UCO of Clinical Psychiatry, University of Trieste, Trieste, Italy
    Curr Med Res Opin 20:1747-52. 2004
    ..We analysed the effects of donepezil, rivastigmine and galantamine, prescribed for the treatment of Alzheimer disease in a real-world setting in Italy...
  64. ncbi Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study
    Peter M Aupperle
    Division of Geriatric Psychiatry, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, Piscataway, NJ, USA
    Curr Med Res Opin 20:1605-12. 2004
    ..To evaluate the safety and efficacy of long-term treatment with rivastigmine (3-12 mg/day) and its effects on neuropsychiatric and behavioral disturbances in nursing home patients with moderate to severe probable Alzheimer's disease (AD)...
  65. ncbi Rivastigmine as a modulator of the neuronal glutamate transporter rEAAC1 mRNA expression
    Josefine Andin
    Department of Neuroscience and Locomotion, Division of Geriatric Medicine, Linkopings Universitet Hospital, SE 581 85 Linkoping, Sweden
    Dement Geriatr Cogn Disord 19:18-23. 2005
    ..These results provide the first evidence that the glutamatergic system is modulated following acetylcholinesterase inhibition by rivastigmine, a finding, which is likely to be of importance for the clinical effects...
  66. ncbi Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer's disease
    Sanford I Finkel
    Department of Psychiatry, University of Chicago Medical School, Chicago, Illinois, USA
    Clin Ther 26:980-90. 2004
    ..Regulatory studies of rivastigmine in AD were not designed to evaluate effects on BPSD, but further investigation of rivastigmine in AD was prompted by later studies demonstrating behavioral benefits in other types of dementia...
  67. doi Pharmacokinetics and bioavailability of the novel rivastigmine transdermal patch versus rivastigmine oral solution in healthy elderly subjects
    Gilbert Lefèvre
    Novartis Pharma AG, Exploratory Development, WSJ 210 4 25, CH 4002 Basel, Switzerland
    J Clin Pharmacol 48:246-52. 2008
  68. ncbi A cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer's disease
    Roberto Raschetti
    National Center for Epidemiology, National Institute of Health, Viale Regina Elena 299, 00161, Rome, Italy
    Eur J Clin Pharmacol 61:361-8. 2005
    ....
  69. ncbi Glucosamine-induced increase in Akt phosphorylation corresponds to increased endoplasmic reticulum stress in astroglial cells
    J Aaron Matthews
    Department of Chemistry, University of South Florida, 4202 East Fowler Ave, SCA 400, Tampa, FL 33620, USA
    Mol Cell Biochem 298:109-23. 2007
    ..The mechanism by which STZ increases Akt phosphorylation, however, remains unknown...
  70. ncbi Analysis of PUGNAc and NAG-thiazoline as transition state analogues for human O-GlcNAcase: mechanistic and structural insights into inhibitor selectivity and transition state poise
    Garrett E Whitworth
    Department of Chemistry, Simon Fraser University, 8888 University Drive, Burnaby, British Columbia, Canada
    J Am Chem Soc 129:635-44. 2007
    ....
  71. ncbi The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease
    E Loveman
    Southampton Health Technology Assessments Centre, Wessex Institute for Health Research and Development, University of Southampton, UK
    Health Technol Assess 10:iii-iv, ix-xi, 1-160. 2006
    ....
  72. ncbi Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology
    Jacques Touchon
    CHU, INSERM 361, Montpellier, France
    Curr Med Res Opin 22:49-59. 2006
    ..This retrospective analysis investigated whether AD patients with and without symptoms suggesting concomitant Lewy body pathology demonstrated different responses to therapy...
  73. ncbi Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET
    Ahmadul Kadir
    Karolinska Institute, Department of Neurobiology, Care Sciences and Society, Division of Molecular Neuropharmacology, Karolinska University Hospital Huddinge, Novum floor 5, 141 86, Stockholm, Sweden
    Psychopharmacology (Berl) 191:1005-14. 2007
    ..Thus, we used positron emission tomography (PET) technique as a sensitive approach to assess longitudinal changes in the nicotine binding sites in the brains of patients with AD...
  74. ncbi A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease
    A Takeda
    Southampton Health Technology Assessments Centre SHTAC, University of Southampton, Southampton, UK
    Int J Geriatr Psychiatry 21:17-28. 2006
    ..This article provides the latest evidence that NICE will be using as part of this appraisal process...
  75. ncbi Benefits of rivastigmine on attention in dementia associated with Parkinson disease
    K A Wesnes
    Cognitive Drug Research, Goring on Thames, United Kingdom
    Neurology 65:1654-6. 2005
    ..Significant benefits of rivastigmine over placebo were seen on all aspects of attention assessed: sustained attention, focused attention, consistence of responding, and central processing speed...
  76. ncbi Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer's plaques and tangles
    Mariam F Eskander
    Laboratory for Neurodegenerative and Aging Research, Department of Medicine Neuroscience, Harvard Medical School and Division of Gerontology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Brain Res 1060:144-52. 2005
    ..Thus, at the therapeutic concentrations used, rivastigmine is likely to result in inhibition of pathological cholinesterases, with the potential of interfering with the disease process...
  77. ncbi Pharmacokinetic rationale for the rivastigmine patch
    Jeffrey Cummings
    UCLA Alzheimer s Center, Los Angeles, CA 90095 7226, USA
    Neurology 69:S10-3. 2007
    ..The potential of a patch to improve the tolerability of rivastigmine (e.g., nausea and vomiting) while permitting similar exposure to the highest doses of capsules may, in turn, lead to improved efficacy and compliance...
  78. pmc Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials
    Hanna Kaduszkiewicz
    Department of Primary Medical Care, Center of Psychosocial Medicine, University Medical Center Hamburg Eppendorf, Martinistrasse 52, D 20246 Hamburg, Germany
    BMJ 331:321-7. 2005
    ..Three cholinesterase inhibitors are currently recommended: donepezil, rivastigmine, and galantamine. This review assessed the scientific evidence for the recommendation of these agents...
  79. ncbi O-GlcNAc modification on IRS-1 and Akt2 by PUGNAc inhibits their phosphorylation and induces insulin resistance in rat primary adipocytes
    Seung Yoon Park
    Department of Biochemistry, College of Medicine, Dongguk University, Gyeongju 780 714, Korea
    Exp Mol Med 37:220-9. 2005
    ....
  80. ncbi Association with the cholinergic precursor choline alphoscerate and the cholinesterase inhibitor rivastigmine: an approach for enhancing cholinergic neurotransmission
    Francesco Amenta
    Sezione di Anatomia Umana, Dipartimento di Medicina Sperimentale e Sanità Pubblica, Universita di Camerino, Via Scalzino 3, 62032 Camerino, Italy
    Mech Ageing Dev 127:173-9. 2006
    ....
  81. ncbi Rivastigmine in subcortical vascular dementia: an open 22-month study
    Rita Moretti
    Dipartimento di Fisiologia e Patologia, Universita degli Studi di Trieste, Trieste, Italy
    J Neurol Sci 203:141-6. 2002
    ..These benefits may reflect the drug's dual inhibitory effects on the cholinergic system, and its particular activity in frontal areas of the brain. A large, double-blind study of rivastigmine in patients with VaD would be worthwhile...
  82. ncbi Long-lasting acetylcholinesterase splice variations in anticholinesterase-treated Alzheimer's disease patients
    T Darreh-Shori
    Karolinska Institute, Neurotec Department, Stockholm, Sweden
    J Neurochem 88:1102-13. 2004
    ..0001). Thus, evaluation of changes in the composition of CSF AChE variants may yield important information referring to the therapeutic efficacy and/or development of drug tolerance in AD patients treated with anti-cholinesterases...
  83. ncbi Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition
    C G Ballard
    Newcastle General Hospital, Newcastle upon Tyne, UK
    Eur Neurol 47:64-70. 2002
    ..It is a priority for future clinical trials to determine whether agents with dual inhibition properties have greater clinical efficacy...
  84. pmc Elevated nucleocytoplasmic glycosylation by O-GlcNAc results in insulin resistance associated with defects in Akt activation in 3T3-L1 adipocytes
    Keith Vosseller
    Department of Biological Chemistry, Johns Hopkins University School of Medicine, 725 North Wolfe Street, Baltimore, MD 21205, USA
    Proc Natl Acad Sci U S A 99:5313-8. 2002
    ..These results suggest that elevation of O-GlcNAc levels attenuate insulin signaling and contribute to the mechanism by which increased flux through the HSP leads to insulin resistance in adipocytes...
  85. ncbi Felbamate inhibits cloned voltage-dependent Na+ channels from human and rat brain
    M Taglialatela
    Department of Neuroscience, School of Medicine, University of Naples Federico II, Italy
    Eur J Pharmacol 316:373-7. 1996
    ..This study provides an additional mechanism by which felbamate might exert its wide-spectrum anticonvulsant and neuroprotective action...
  86. ncbi Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness
    Christina Wolfson
    Centre for Clinical Epidemiology and Community Studies, S M B D Jewish General Hospital, Montreal, Quebec, Canada
    Clin Ther 24:862-86; discussion 837. 2002
    ..Various drugs have been approved for the treatment of Alzheimer's disease (AD) in the United States and Canada, including donepezil and rivastigmine, although questions remain as to their efficacy, effectiveness, and long-term benefits...
  87. ncbi Rivastigmine in prevention of delirium in a 65 years old man with Parkinson's disease
    Paul L J Dautzenberg
    Int J Geriatr Psychiatry 18:555-6. 2003
  88. ncbi Use-dependent inhibition of the N-methyl-D-aspartate currents by felbamate: a gating modifier with selective binding to the desensitized channels
    Chung Chin Kuo
    Department of Physiology, National Taiwan University College of Medicine, Taipei, Taiwan
    Mol Pharmacol 65:370-80. 2004
    ..Because the inhibitory effect is apparent only when there is excessive NMDA exposure, FBM may effectively inhibit many seizure discharges but preserve most normal neuronal firings...
  89. ncbi A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease
    D G Wilkinson
    Memory Assessment and Research Centre, Moorgreen Hospital, Southampton, UK
    Int J Clin Pract 56:441-6. 2002
    ..Thus, using the recommended dosing schedules, donepezil was better tolerated with fewer discontinuations due to AEs, and both agents improved cognition to a similar extent...
  90. ncbi Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months
    T Darreh-Shori
    Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    Neurology 59:563-72. 2002
    ..To study the long-term dual inhibitory effects of rivastigmine on acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) in patients with AD...
  91. ncbi Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series
    R Bullock
    Department of Old Age Psychiatry, Kingshill Research Centre, Victoria Hospital, Swindon, UK
    Curr Med Res Opin 18:258-64. 2002
    ..A large, placebo-controlled study is warranted to ascertain the full clinical profile of rivastigmine in Parkinson's disease dementia...
  92. ncbi Prolonged incubation in PUGNAc results in increased protein O-Linked glycosylation and insulin resistance in rat skeletal muscle
    Edward B Arias
    Department of Kinesiology, University of Wisconsin Madison, Madison, Wisconsin, USA
    Diabetes 53:921-30. 2004
    ....
  93. ncbi Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial
    P J Reading
    Department of Neurology, Regional Neurosciences Centre, Newcastle General Hospital, Newcastle upon Tyne, United Kingdom
    Mov Disord 16:1171-4. 2001
    ..In a group of 12 patients, hallucinations, sleep disturbance, and carer distress were all improved and cognitive performance significantly enhanced by the drug...
  94. ncbi Subtype-selective antagonism of N-methyl-D-aspartate receptors by felbamate: insights into the mechanism of action
    N W Kleckner
    Department of Biology, Bates College, Lewiston, Maine
    J Pharmacol Exp Ther 289:886-94. 1999
    ..These results suggest that the unique clinical profile of felbamate is due in part to an interaction with the NR1-2B subtype of NMDA receptor...
  95. ncbi Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer's disease in comparison with untreated AD and MCI patients
    O Almkvist
    Neurotec Department, Karolinska Institutet, Stockholm, Sweden
    Eur J Neurol 11:253-61. 2004
    ..In conclusion, a clear beneficial effect of rivastigmine was shown on cognitive function for patients with mild AD and plasma values of ChE inhibition were associated with attention...
  96. ncbi Rivastigmine in vascular dementia
    Rita Moretti
    Universita degli Studi di Trieste, Istituto di Clinica Neurologica, Ospedale di Cattinara, 34149 Trieste, Italy
    Expert Opin Pharmacother 5:1399-410. 2004
    ..A large, double-blind study of rivastigmine in patients with VaD is clearly warranted...
  97. ncbi Rivastigmine. A review of its use in Alzheimer's disease
    C M Spencer
    Adis International Limited, Auckland, New Zealand
    Drugs Aging 13:391-411. 1998
    ..However, compared with placebo, rivastigmine more commonly caused adverse events resulting in treatment withdrawal. These events were most frequently gastrointestinal and were more common in women...
  98. ncbi Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease
    Craig W Ritchie
    Department of Psychiatry and Behavioural Science, Royal Free and University College Medical School, University College London, Royal Free Campus, Rowland Hill Street, London, UK NW3 2PF
    Am J Geriatr Psychiatry 12:358-69. 2004
    ..However, both galantamine and rivastigmine were associated with a greater risk of trial dropout than placebo, especially at higher dosing levels...
  99. ncbi Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study
    I McKeith
    Institute for the Health of the Elderly, University of Newcastle upon Tyne, UK
    Lancet 356:2031-6. 2000
    ..Rivastigmine, a cholinesterase inhibitor, was tested in a group of clinically characterised patients with Lewy-body dementia...
  100. ncbi A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease
    M Farlow
    Department of Neurology, Indiana University School of Medicine, Indianapolis, IN 46202 5111, USA
    Eur Neurol 44:236-41. 2000
    ..By 52 weeks, patients originally treated with 6-12 mg/day rivastigmine had significantly better cognitive function than patients originally treated with placebo...
  101. ncbi Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer's disease
    E Stefanova
    Division of Molecular Neuropharmacology, Neurotec Department, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    J Neural Transm 113:205-18. 2006
    ..5-12'mg) of rivastigmine. These results suggest a stabilization effect of rivastigmine on CMRglc in mild AD patients receiving long-term rivastigmine treatment...

Research Grants18

  1. Rivastigmine as a Treatment for Methamphetamine Dependence
    Richard De La Garza; Fiscal Year: 2010
    ..The knowledge gained may ultimately support development and implementation of evidence-based treatments for MA dependence, a drug abuse problem with tremendous public health impact. ..
  2. Transdisciplinary Imaging Genetics Center (1 of 2)(RMI)
    Steven Potkin; Fiscal Year: 2006
    ..The new knowledge generated by the Center holds considerable promise for improving diagnosis and treatment of mental illness. [unreadable] [unreadable]..
  3. Development of Inventory of Depressive Symptomatology
    PUDUGRAMAM DORAISWAMY; Fiscal Year: 2005
    ..g., anxiety, irritability) (IDS-C and SR) that are in the public domain for use with patients across the age spans seen in practice and in research. ..
  4. Treatment Outcomes of Vascular Depression
    PUDUGRAMAM DORAISWAMY; Fiscal Year: 2005
    ..The proposed trial will provide information of value to the practitioner and also provide data to build a more comprehensive model of the prognostic impact of frontal-subcortical brain changes on the outcome of late-life depression. ..
  5. Pilot Study of Huperzine A in Alzheimer's Disease
    Paul Aisen; Fiscal Year: 2003
    ....
  6. BRAIN GALANIN RECEPTORS AND EPILEPSY
    Andrey Mazarati; Fiscal Year: 2006
    ..abstract_text> ..
  7. Guanfacine Treatment for Prefrontal Cognitive Dysfunction in Elderly Subjects
    Christopher H van Dyck; Fiscal Year: 2010
    ..This Pilot Clinical Trial will provide essential preliminary data for a subsequent full-scale trial of guanfacine for prefrontally-mediated cognitive dysfunction in elderly subjects. ..
  8. GI PEPTIDE SIGNALING THROUGH TYROSINE PHOSPHORYLATION
    JUAN ENRIQUE ROZENGURT; Fiscal Year: 2010
    ....
  9. The 5-HT7 receptor in models of psychiatric disorders
    PETER HEDLUND; Fiscal Year: 2009
    ..These studies will provide valuable data for possible improvements of the therapy for disorders that afflicts large groups of the population. ..
  10. MENTAL DISORDERS OF AGING--ANTIINFLAMMATION IN AD
    Gary Small; Fiscal Year: 2003
    ....
  11. RISK MARKERS FOR DEMENTIA AFTER STROKE
    David Nyenhuis; Fiscal Year: 2004
    ..They state that refinement in our knowledge of mechanisms and causes for dementia in stroke patients may lead to an improvement in prevention and treatment strategies. ..
  12. The International Symposium on Regulatory Peptides
    JUAN ROZENGURT; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  13. Validation of the NINDS VCI Neuropsychology Protocols
    David Nyenhuis; Fiscal Year: 2009
    ..Reliable and valid VCI neuropsychology test protocols are a necessary first step to improved diagnostic criteria and a better understanding of both the mechanisms of VCI and the development of new treatment options. ..
  14. FMRI in Pre-Symptomatic PS1-related Alzheimer's Disease
    John Ringman; Fiscal Year: 2005
    ..UCI, with its strong dementia research program, growing MRI capabilities and opportunity to collaborate at the nearby UCLA Brain Imaging Center, is an excellent environment for this endeavor. ..